Back to search
Chemotherapeutic Agent Toxicity
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Chemotherapeutic Agent Toxicity trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Chemotherapeutic Agent Toxicity trials you may qualify forGALENOS 2 is a single-arm, single-center, phase II interventional study designed to evaluate the effects of a galenic immunonutrition dietary supplement in pati…
GALENOS 1 is a prospective observational study designed to explore longitudinal changes in nutritional status and body composition in patients with head and nec…
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cance…
The purpose of this pilot study is to determine the safety and feasibility of a daily 3-minute hand-held vibration therapy intervention to reduce the severity o…
This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder…
In recent years, immunotherapy has been postulated as one of the most effective strategy in the fight against cancer. The greatest success in this field has bee…
The study will include approximately 150 adult outpatients diagnosed with solid tumors who are currently receiving chemotherapy. Both early and advanced stage p…
This phase II trial studies the side effects and how well lapatinib ditosylate and trastuzumab work in treating older patients with human epidermal growth facto…
Cancer is a major worldwide health problem, with around 330.000 new annual cases only in the UK. Improved survival rates due to better treatments have lead to a…